Work Experience
1. Former Director, Department of Endocrinology & Metabolism of Zhongshan Hospital, Fudan University;
2. Member of standing committee member of Chinese Society of Endocrinology (CSE);
3. Deputy Chairman of Chinese Endocrinologist Association (CEA);
4. Director of the Integrated Traditional and Western Medicine Research Group, Chinese Society of Endocrinology (CSE);
5. The founder and the former director of Liver Disease and Metabolic Disorders Research Group, Chinese Society of Endocrinology (CSE);
6. Former president of Shanghai Society of Endocrinology.
Research Interests
1. Established “The Shanghai Changfeng Study” which is a community-based prospective cohort study of multiple chronic diseases among middle-aged and elderly. The objectives of this study is to explore the related mechanism between obesity, adiposis hepatica and the diseases of diabetes, angiocardiopathy, osteoporosis and some tumors
2. To investigate the mechanisms of obesity and non-alchohol fatty liver diseases
3. To explore the mechanisms of Berberin in regulating glucose and lipids metabolic pathway
4. To initiate clinical trials for assessing new drugs or new indications for treating diabetes, obesity, NAFLD
Awards
1. Shanghai Outstanding Patent Invention Award, 2nd prize(2002);
2. Shanghai Medical Science and Technology Award, 2nd prize(2003);
3. Ministry of Education, Science and Technology Progress Award, 2nd price(2007);
4. Shanghai Science and Technology of Integrative Medicine Award, 3rd prize(2010);
5. Shanghai Medical Science and Technology Award, 2nd prize(2010);
6. Chinese Society of Endocrinology Scientific Achievements Award(2015);
7. Shanghai Medical Science and Technology Award, 2nd prize(2015);
Selected Publications
1.Xin Gao*, Albert Hofman, Yu Hu, Huandong Lin, Chouwen Zhu, Johannes Jeekel, Xuejuan Jin , Jiyao Wang, Jian Gao, Yiqing Yin, Naiqing Zhao The Shanghai Changfeng Study: a community-based prospective cohort study of chronic diseases among middle-aged and elderly: objectives and design,European Journal of Epidemiology,2010,25(12):885-893.
2.Xia MF, Yan HM, He WY, Li XM, Li CL, Yao XZ, Li RK, Zeng MS,Gao X*. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method.Obesity (Silver Spring). 2012 Feb;20(2):444-52.
3. Li X, LingY, LuD, LuZ, LiuY, ChenH,Gao X*, Common polymorphism rs11191548 near the CYP17A1 gene is associated with hypertension and systolic blood pressure in the Han Chinese population.American Journal of Hypertension,2013,26(4):465-472.
4. Lin H, Li Q, Hu Y, Zhu C, Ma H, Gao J, Wu J, Shen H, Jiang W, Zhao N, Yin Y, Pan B, Jeekel J, Hofman A,Gao X*. The prevalence of multiple non-communicable diseases among middle-aged and elderly people: the Shanghai Changfeng Study.Eur J Epidemiol. 2017 Feb;32(2):159-163.
5. Sun Y, Xia M, Yan H, Han Y, Zhang F, Hu Z, Cui A, Ma F, Liu Z, Gong Q, Chen X,Gao J, Bian H, Tan Y, Li Y*,Gao X*. Berberine Attenuates Hepatic Steatosis and Enhances Energy Expenditure in Mice by Inducing Autophagy and Fibroblast Growth Factor 21.Br J Pharmacol. 2017 Oct 24. doi: 10.1111/bph.14079. [Epub ahead of print] PubMed PMID: 29065221
